Insight Molecular Diagnostics Inc stock is traded at $2.10, with a volume of 13,588. It is down -2.10% in the last 24 hours and down -30.40% over the past month. Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Previous Close:
$2.14
Open:
$2.16
24h Volume:
13,588
Relative Volume:
0.11
Market Cap:
$68.56M
Revenue:
$1.95M
Net Income/Loss:
-$47.84M
P/E Ratio:
-
EPS:
-$1.48
Net Cash Flow:
-$27.46M
1W Performance:
-16.20%
1M Performance:
-30.40%
6M Performance:
-67.32%
1Y Performance:
-71.69%
1-Day Range:
$2.03$2.16
1-Week Range:
$2.03$2.65
52-Week Range:
$2.03$8.50
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Name
Insight Molecular Diagnostics IncSector
HealthcareIndustry
Diagnostics & ResearchPhone
949-409-7600Address
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS